Intriguingly, a clinical study [61] with only ten CD patients showed that treatment with LL-Thy12 was safe, with minor adverse events, and a decrease in disease activity was observed in these patients, indicating that the use of gm probiotics for the mucosal delivery of IL-10 might be a feasible strategy for treating IBD. Here, IL10 is linked to inflammatory bowel disease.